Goldman Sachs cuts Regenxbio target to $10

Goldman Sachs cuts Regenxbio (NASDAQ:RGNX) price target to $10 from $12 on RGX-202 regulatory uncertainty. Stock down 41% to $6.25.

ByChloe Hall- Senior Editor

2026-05-15 09:54|Last updated: 2026-05-15 09:55

Goldman Sachs cuts Regenxbio target to $10 — Photo: Prepared by Bond.az

Goldman Sachs has lowered its price target on Regenxbio (NASDAQ:RGNX) to $10 from $12, maintaining a Neutral rating. The stock has plunged 41% over the past week to $6.25, near its 52-week low.

The move comes amid regulatory uncertainty for RGX-202, with the company planning to file in early 2027. Analyst Paul Choi noted Q1 2026 results and an operational update.

Investors are questioning the regulatory setup for RGX-202 after topline data. Goldman awaits interim NSAA updates and wAMD topline data.

Two key catalysts identified: AFFINITY interim NSAA results over 2026, and topline data for ABBV-RGX-314 (with AbbVie) in Q4 2026 for wAMD.

According to Bond.az analysis, the stock appears undervalued with a Fair Value of $11.70.

More News

2026-06-01 12:02

743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

ANALYST RATINGS →

2026-06-01 12:01

475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

ANALYST RATINGS →

2026-06-01 12:00

842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

ANALYST RATINGS →

2026-06-01 10:33

714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

ANALYST RATINGS →

2026-06-01 10:32

730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

ANALYST RATINGS →

2026-06-01 10:32

238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

ANALYST RATINGS →

2026-06-01 10:30

651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

ANALYST RATINGS →

2026-06-01 10:03

748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

ANALYST RATINGS →

2026-06-01 09:02

551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

ANALYST RATINGS →

2026-06-01 08:31

594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

ANALYST RATINGS →

2026-06-01 08:05

946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

ANALYST RATINGS →

2026-06-01 08:02

892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

ANALYST RATINGS →

...